In this study, positive correlation of lnc‐ITSN1‐2 expression with the NIHSS score and inflammatory markers levels (including CRP, TNF‐α, IL‐1β, IL‐6, IL‐8, IL‐17, and IL‐22) and negative correlation of lnc‐ITSN1‐2 expression with potential targeting miRNAs (including miR‐107, miR‐125a, and miR‐146a), which indicated that lnc‐ITSN1‐2 high expression was correlated with worse disease severity and increased inflammation in AIS patients, were discovered. The gene discussed is IL22; the disease is androgen insensitivity syndrome.